Comirnaty (Pfizer-BioNTech COVID-19 Vaccine)

Chemical NameCOVID-19 Vaccine, mRNA
Dosage FormInjection (intramuscular; 0.3 mL)
Drug ClassVaccines
SystemRespiratory
CompanyPfizer-BioNTech
Approval Year2021

Indication

  • Indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older
Last updated on 3/28/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pfizer-BioNTech COVID-19 (BNT162b2) Vaccine (SARS-CoV-2 vaccine) Prescribing Information.2021Pfizer Inc., New York, NY; BioNTech Manufacturing GmbH, Mainz, Germany
Document TitleYearSource
Assessment report: comirnaty. 2021EMA